. List of food to be avoided for the three days prior to clinical visits. Dihomo-gamma-linolenic acid, C20:3 n-6 6.4 ± 1.3 5.8 ± 0.6 6.4 ± 0.7 6.0 ± 0.5 5.9 ± 0.7 5.9 ± 0.5
Food rich in omega 3 Fatty acids
Arachidonic acid, C20:4 n-6 24.8 ± 3.5 24.2 ± 2.2 25.5 ± 3.0 23.7 ± 2.3 23.9 ± 3.6 24.1 ± 2.4
Eicosapentaenoic acid, C20:5 n-3 234 3.0 ± 0.4 3.5 ± 0.6 3.3 ± 0.4 8.5 ± 1.5* 3.7 ± 0.7 5.1 ± 0.6 Docosapentaenoic acid, C22:5 n-3 4 0.9 ± 0.1 1.0 ± 0.2 1.1 ± 0.2 0.7 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 Docosahexaenoic acid, C22:6 n-3 234 6.6 ± 1.3 6.4 ± 0.7 6.7 ± 0.8 7.5 ± 0.8 6.4 ± 0.9 12.0 ± 1.3* Table S4 . Supporting data for Figure 1 : Augmentation index (%) at baseline and in response to treatment.
23.6 ± 0.9 22.5 ± 0.9 24.9 ± 1.0 21.0 ± 0.9 25.5 ± 1.2 21.1 ± 1.1* Data are presented as mean ± SEM (n = 26). CO: Control oil; ERO: EPA rich oil; DRO: DHA rich oil. Two-factor repeated measures ANOVA. P, time < 0.010, P, time*treatment = 0.005. * indicates significantly different (P = 0.047) change scores for DRO when compared to CO. 
